Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.46 - $40.4 $44,688 - $73,810
1,827 Added 170.11%
2,901 $77,000
Q1 2024

May 03, 2024

BUY
$36.38 - $52.31 $39,072 - $56,180
1,074 New
1,074 $44,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.